在接受心脏手术的患者中,复合因子VIIa与前列红素复合度相对应:系统性审查和元分析
Matthew Cadd1, Daniel Puntis1, Sam Bullard2
1Anaesthetic Department, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom.
Journal of cardiothoracic and vascular anesthesia
|October 22, 2025
概括
与复合因子VIIa (rFVIIa) 相比,血组复合 (PCC) 降低了心脏手术患者的胸管输出和血栓栓塞事件,而不会增加急性损伤 (AKI) 或死亡率.
科学领域:
- 心血管外科心血管外科
- 血液学 血液学 血液学
- 临界护理医学 临界护理医学
背景情况:
- 术期间出血在心脏手术中很常见,导致发病率和死亡率增加.
- 血栓复合缩剂 (PCC) 和复合因子VIIa (rFVIIa) 用于控制出血,但rFVIIa引起了人们对急性损伤 (AKI) 和血栓塞栓事件的担忧.
研究的目的:
- 在成人心脏手术患者中系统地审查和元分析比较PCC和rFVIIa的证据.
- 评估PCC与rFVIIa对胸管输出,不良事件和死亡率的影响.
主要方法:
- 七项追溯观察性研究的系统综述和元分析.
- 包括962名接受心脏手术的成年患者.
主要成果:
- PCC显著降低了胸腔管的总输出 (平均差异:-301.01毫升).
- PCC与血栓栓塞性疾病 (OR 0.55) 和深静脉血栓症 (OR 0.28) 的降低率有关.
- 在PCC和rFVIIa组之间,没有观察到AKI发病率或死亡率的显著差异.
结论:
- PCC在减少胸管输出和血栓塞栓性疾病发病率方面表现出有益作用.
- 在心脏手术中,PCC似乎是rFVIIa的安全替代品,没有增加AKI或死亡风险.
相关概念视频
Venous Thrombosis III: Interprofessional Care
278
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
278
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Extrinsic and Intrinsic Pathways of Hemostasis
12.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
12.0K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
286
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
286
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
311
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
311


